OSE Immunotherapeutics Share Price
Stocks
OSE
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Euronext Paris
07:06:19 29/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 2.120 EUR | -3.20% |
|
+3.82% | -58.83% |
| Market Cap | 5.15Cr 5.74Cr 4.76Cr 4.31Cr 8.06Cr 546.78Cr 8.16Cr 57Cr 23Cr 286.12Cr 22Cr 21Cr 908.33Cr | P/E 2026 * |
-1.68x | P/E 2027 * | -1.93x |
|---|---|---|---|---|---|
| Enterprise Value | 8.86Cr 9.88Cr 8.19Cr 7.42Cr 14Cr 940.87Cr 14Cr 98Cr 39Cr 492.34Cr 37Cr 36Cr 1.56TCr | EV / Sales 2026 * |
18.1x | EV / Sales 2027 * | 10.5x |
| Free-Float |
78.15% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| OSE | Real-time | |
Börse Stuttgart
| 6OP | Delayed | |
|
CBOE
| OSEp | Real-time | |
|
Tradegate
| 6OP | Real-time | |
|
Deutsche Boerse AG
| 6OP | Delayed | |
|
CBOE
| 0RAD | Real-time | |
|
Boerse Muenchen
| 6OP | Real-time |
Last Transcript: OSE Immunotherapeutics
| 1 day | -3.20% | ||
| 1 week | +3.82% | ||
| Current month | -5.36% | ||
| 1 month | -5.86% | ||
| 3 months | -34.12% | ||
| 6 months | -46.38% | ||
| Current year | -58.83% |
| 1 week | 1.98 |  | 2.33 |
| 1 month | 1.98 | | 2.33 |
| Current year | 1.98 | | 5.9 |
| 1 year | 1.98 | | 6.1 |
| 3 years | 1.98 | | 11.58 |
| 5 years | 1.98 | | 12.28 |
| 10 years | 1.98 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Le Bozec
CEO | Chief Executive Officer | - | 30/09/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 20/08/2025 |
Aurore Morello
CTO | Chief Tech/Sci/R&D Officer | - | 02/12/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Markus J. Cappel
CHM | Chairman | 65 | 30/09/2025 |
Jonathan Cool
BRD | Director/Board Member | 66 | 30/09/2025 |
Marc Le Bozec
BRD | Director/Board Member | - | 30/09/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/11/24 | Sell | Director | 30,000 | 0.1375% | ||
| 12/11/24 | Sell | Chief Administrative Officer | 10,000 | 0.0458% | ||
| 21/06/24 | Exercice | Director | 10,000 | 0.0459% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.20% | +3.82% | -64.10% | -52.14% | 5.74Cr | |
| +0.65% | -3.36% | +36.98% | +60.50% | 6.41TCr | |
| +1.93% | +3.65% | +13.31% | +85.64% | 5.55TCr | |
| +1.84% | +1.91% | +13.19% | +105.52% | 5.3TCr | |
| -1.11% | +0.87% | +27.92% | +55.07% | 4.6TCr | |
| +0.11% | -3.39% | +17.83% | +119.04% | 4.25TCr | |
| +0.60% | -2.86% | +224.43% | +914.08% | 4.04TCr | |
| +0.64% | -3.95% | +11.15% | +45.57% | 3.23TCr | |
| +0.14% | +43.26% | +104.52% | +90.96% | 3.45TCr | |
| -2.72% | -0.44% | +23.18% | -10.77% | 2.42TCr | |
| Average | -0.16% | +4.25% | +40.84% | +141.35% | 3.93TCr | |
| Weighted average by Cap. | +0.42% | +3.49% | +49.54% | +160.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 49L 54.61L 45.3L 41.03L 76.65L 52Cr 77.58L 5.42Cr 2.16Cr 27Cr 2.05Cr 2.01Cr 86Cr | 1.05Cr 1.17Cr 97.35L 88.17L 1.65Cr 111.78Cr 1.67Cr 12Cr 4.64Cr 58Cr 4.4Cr 4.31Cr 185.69Cr |
| Net income | -3.06Cr -3.41Cr -2.83Cr -2.56Cr -4.78Cr -324.68Cr -4.84Cr -34Cr -13Cr -169.9Cr -13Cr -13Cr -539.37Cr | -2.15Cr -2.39Cr -1.98Cr -1.8Cr -3.36Cr -227.88Cr -3.4Cr -24Cr -9.45Cr -119.24Cr -8.98Cr -8.79Cr -378.56Cr |
| Net Debt | 3.71Cr 4.14Cr 3.43Cr 3.11Cr 5.81Cr 394.08Cr 5.88Cr 41Cr 16Cr 206.22Cr 16Cr 15Cr 654.66Cr | 5.93Cr 6.6Cr 5.48Cr 4.96Cr 9.27Cr 628.97Cr 9.38Cr 65Cr 26Cr 329.13Cr 25Cr 24Cr 1.04TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/26/29 | €2.120 | -3.20% | 1,03,077 |
| 28/26/28 | €2.190 | +3.11% | 5,34,530 |
| 27/26/27 | €2.124 | +3.21% | 1,45,682 |
| 26/26/26 | €2.058 | +2.69% | 1,15,812 |
| 23/26/23 | €2.004 | -1.86% | 1,06,689 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- OSE Stock
Select your edition
All financial news and data tailored to specific country editions
